Phocas Financial Corp. Cuts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Phocas Financial Corp. lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 83,764 shares of the medical equipment provider’s stock after selling 5,227 shares during the period. Phocas Financial Corp.’s holdings in Lantheus were worth $9,193,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after purchasing an additional 389,828 shares in the last quarter. Farallon Capital Management LLC increased its position in shares of Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock worth $182,999,000 after acquiring an additional 796,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Lantheus by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after acquiring an additional 19,071 shares in the last quarter. Swedbank AB boosted its position in Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares during the period. Finally, Boston Partners increased its holdings in Lantheus by 21.2% in the 1st quarter. Boston Partners now owns 681,281 shares of the medical equipment provider’s stock valued at $42,696,000 after purchasing an additional 119,156 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of LNTH opened at $76.22 on Tuesday. The firm has a fifty day moving average of $104.95 and a 200-day moving average of $96.65. The company has a market cap of $5.30 billion, a price-to-earnings ratio of 12.68 and a beta of 0.51. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89.

Analyst Ratings Changes

A number of brokerages have commented on LNTH. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Finally, B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.